WEREWOLF THERAPEUTICS INC. - COMMON STOCK

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

03 May 2024 07:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 Apr 2024 10:05:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

23 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

05 Apr 2024 16:30:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

04 Apr 2024 16:30:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

07 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

06 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

05 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

08 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

22 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

14 Nov 2023 16:25:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

03 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

31 Oct 2023 09:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

27 Sep 2023 09:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

11 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

05 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

10 Aug 2023 07:10:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Present at the Jefferies Healthcare Conference

01 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

11 May 2023 07:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate in May Investor Conferences

01 May 2023 07:00:00 By Nasdaq GlobeNewswire